Please check your internet connection and try again.
# Walethmade bromide (Valethamate bromide)
## Overview
Valethamate bromide is a quaternary ammonium anticholinergic agent with spasmolytic properties. It acts by antagonizing muscarinic receptors and exerting a direct inhibitory effect on smooth muscle fibers. It is primarily used to relieve visceral spasms.
## Primary Indications
* Relief of smooth muscle spasms of the gastrointestinal, biliary, and genitourinary tracts.
* Cervical dilation during labor (off-label/regional use).
## Adult Dosing
* **Oral:** 10 mg to 20 mg three times daily, as needed. Maximum daily dose should not exceed 60 mg.
* **Parenteral (IM/IV):** 8 mg to 16 mg, administered slowly. May repeat every 4 to 6 hours as required.
## Pediatric Dosing
Safety and efficacy in children have not been rigorously established. Use is generally avoided unless specified by institutional protocol. If necessary, doses are typically calculated based on weight (e.g., 0.1 mg/kg to 0.2 mg/kg per dose), but clinical guidance is extremely limited.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No standardized data available. Use with caution; lower initial doses or increased dosing intervals are recommended if impaired clearance is suspected.
* **Elderly:** Increased risk of anticholinergic side effects (e.g., confusion, urinary retention, constipation). Use the lowest effective dose.
## Contraindications
* Hypersensitivity to valethamate or other anticholinergics.
* Narrow-angle glaucoma.
* Mechanical intestinal obstruction or paralytic ileus.
* Prostatic hypertrophy or bladder neck obstruction.
* Myasthenia gravis.
* Tachycardia or unstable cardiovascular status.
## Adverse Effects
* **Common:** Dry mouth, blurred vision, photophobia, constipation, urinary retention, and tachycardia.
* **Serious:** Severe arrhythmias (rare), exacerbation of glaucoma, mental confusion or delirium (especially in the elderly), and anaphylaxis.
## Key Drug Interactions
* **Other Anticholinergics:** Synergistic additive effects (e.g., antihistamines, tricyclic antidepressants, antipsychotics) increasing the risk of toxicity.
* **Potassium Chloride (Solid dosage forms):** Potential for increased gastrointestinal mucosal ulceration when combined with anticholinergics.
* **Metoclopramide:** Antagonistic effects on GI motility; therapeutic effects of prokinetics may be offset.
## Monitoring
* Monitor heart rate and rhythm, especially with parenteral administration.
* Assess for urinary output/retention.
* Monitor for signs of CNS toxicity (confusion, dizziness, blurred vision).
## Clinical Pearls
* Valethamate is a potent antispasmodic; it does not treat the underlying cause of spasm.
* Avoid use in patients with tachycardia, as the drug can induce heart rate increases through vagolytic actions.
* Note: Availability is highly variable by region; in many countries, it has been superseded by more selective anticholinergics or newer antispasmodic agents. Always confirm availability and local formulary status.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and region. Always consult the most current prescribing information (package insert), local clinical guidelines, and primary pharmacy resources before prescribing or administering any medication.
